Antibody prevalence to mumps in children and adolescents at two years of the introduction of the MMR vaccine

• Main Authors: Armando Méndez-Herrera, Eloísa Arias-Toledo, Miguel Sánchez-Alemán, Ma. Leonidez Olamendi-Portugal, Juan Ruiz-Gómez, José Luis Díaz-Ortega
• Format: Article
• Language: English
• Published: Instituto Nacional de Salud Pública 2017-12-01
• Series: Salud Pública de México
• Subjects: parotiditis; seroprevalencia; vacunación; niños; adolescentes
• Online Access: http://www.saludpublica.mx/index.php/spm/article/view/8138
• ISSN: 0036-3634; 1606-7916

Objective. To assess the prevalence of mumps antibodies in children and adolescents of Mexico, two years after the introduction of the mumps-containing vaccine MMR. Ma­terials and methods. Evaluation of IgG antibodies with a commercial kit of indirect ELISA. Results. 2 111 children (1-9 years) and 2 484 adolescents (10-19 years) were studied. The overall antibody seroprevalence was 70.6% (95% CI 69.3- 71.9), being higher in adolescents (83.0%, 95%CI 81.5-84.5) than in children (56.0%, 95%CI: 53.9-58.11) (OR 3.83, 95%CI 3.34-4.39, p=0.0000000). Children 1 to 2 and 6 to 9 years who were part of the target group of mumps vaccination since 1998, they had higher seroprevalence than the group of 3 to 5 years unvaccinated. Conclusions. Seropositivity in children aged 1 to 2 and 6 to 9 years was probably at­tributable to vaccination during 1998-2000 and in other age groups to natural exposure related to time elapsed in each birth cohort until the study recruitment.